284 related articles for article (PubMed ID: 16191049)
1. Pharmacologic adjuvants to epoetin in the treatment of anemia in patients on hemodialysis.
Berns JS; Mosenkis A
Hemodial Int; 2005 Jan; 9(1):7-22. PubMed ID: 16191049
[TBL] [Abstract][Full Text] [Related]
2. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI.
Eschbach JW
Semin Nephrol; 2000 Jul; 20(4):320-9. PubMed ID: 10928333
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
4. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
5. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
[TBL] [Abstract][Full Text] [Related]
6. [Is the management of anemia in hemodialysis patients improving in France? Results of the DiaNE study].
Kessler M; Landais P; Canivet E; Yver L; Bataille P; Brillet G; Commenges B; Koné S
Nephrol Ther; 2009 Apr; 5(2):114-21. PubMed ID: 19042175
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
8. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management.
Van Wyck DB
Semin Nephrol; 1989 Mar; 9(1 Suppl 2):21-4. PubMed ID: 2669082
[TBL] [Abstract][Full Text] [Related]
9. Epoetin: human recombinant erythropoietin.
Flaharty KK; Grimm AM; Vlasses PH
Clin Pharm; 1989 Nov; 8(11):769-82. PubMed ID: 2680241
[TBL] [Abstract][Full Text] [Related]
10. Managing erythropoietin hyporesponsiveness.
Kwack C; Balakrishnan VS
Semin Dial; 2006; 19(2):146-51. PubMed ID: 16551293
[TBL] [Abstract][Full Text] [Related]
11. Upper limit of serum ferritin: misinterpretation of the 2006 KDOQI anemia guidelines.
Fishbane S
Semin Dial; 2008; 21(3):217-20. PubMed ID: 18248518
[TBL] [Abstract][Full Text] [Related]
12. Ascorbic acid use in hyporesponders to Epoetin alfa.
Gibbs MA
Nephrol Nurs J; 2000 Aug; 27(4):413-5. PubMed ID: 11276634
[TBL] [Abstract][Full Text] [Related]
13. The role of hepcidin in iron homeostasis and anemia in hemodialysis patients.
Eleftheriadis T; Liakopoulos V; Antoniadi G; Kartsios C; Stefanidis I
Semin Dial; 2009; 22(1):70-7. PubMed ID: 19250447
[TBL] [Abstract][Full Text] [Related]
14. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
15. [Principles of iron therapy in hemodialysis patients].
Basić-Jukić N; Kes P; Jurić I
Acta Med Croatica; 2006 Dec; 60(5):457-62. PubMed ID: 17217102
[TBL] [Abstract][Full Text] [Related]
16. IV iron use in patients with higher serum ferritin: case study on anemia in kidney disease.
Larson K
Nephrol Nurs J; 2008; 35(2):184-93; quiz 194-5. PubMed ID: 18472686
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
[TBL] [Abstract][Full Text] [Related]
18. Adjusting i.v. iron and EPO doses in patients on hemodialysis prior to continuing surgery: can we protect our patients education from iron-deficiency anemia?
Deaver K; Bennington L
Nephrol Nurs J; 2006; 33(4):430-7; quiz 438. PubMed ID: 17002001
[TBL] [Abstract][Full Text] [Related]
19. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?
Dukkipati R; Kalantar-Zadeh K
Nephrol News Issues; 2007 Jan; 21(1):34-8. PubMed ID: 17269263
[TBL] [Abstract][Full Text] [Related]
20. The use of iron in patients on chronic dialysis: mistake and misconceptions.
Sakiewicz P; Paganini E
J Nephrol; 1998; 11(1):5-15. PubMed ID: 9561479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
